Modern concepts of the place of acetylsalicylic acid in the treatment of patients with various manifestations of atherothrombosis

The review is devoted to the analysis of the significance of acetylsalicylic acid (ASA) in the primary and secondary prevention of various manifestations of atherothrombosis. The results of the ARRIVE, ASPREE and ASCEND studies are considered, based on which the evidence base for the use of reduced low-dose ASA (75-100 mg) for primary prevention of cardiovascular diseases (CVD), including patients with diabetes mellitus is formed. Nevertheless, the question of the significance of ASA in primary prevention of CVDs has not been finally resolved, because the results of the latest TIPS-3 study, published in 2020, showed that the combination of enteric-coated ASA with a polypill consisting of a statin and three hypotensive drugs, compared with placebo, reduces the frequency of cardiovascular episodes (CVEs) in individuals without CVDs but with average cardiovascular risk. ASA is an immutable component of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS), in patients with coronary heart disease, subjected to planned stenting. Recently, evidence has been obtained about the impact of bleeding on prognostic outcomes, so there is a clear trend to reduce the duration of aspirin therapy in patients with atrial fibrillation and ACS or undergoing planned stenting. A new trend is enhancement of ASA therapy with a second antithrombotic drug in patients with stable manifestations of atherothrombosis with high risk of thrombotic complications. Thus, modern recommendations suggest to enhance ASA therapy with a vascular dose of rivaroxaban (2.5 mg 2 p/day) or a P2Y12-receptor platelet inhibitor. ASA appears to be a classic antiaggregant and an essential partner for new antithrombotic drugs.

1. Patrono C., Bachmann F., Baigent C., Bode C., De Caterina R., Charbonnier B. et al. Expert Consensus Document on the Use of Antiplatelet Agents. The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Eur Heart J. 2004;25(2):166–181. https://doi.org/10.1016/j.ehj.2003.10.013.

2. Antithrombotic Trialists’ Collaboration. Collaborative Meta-Analysis of Randomised Trials of Antiplatelet Therapy for Prevention of Death, Myocardial Infarction, and Stroke in High Risk Patients. BMJ. 2002;324(7329):71–86. https://doi.org/10.1136/bmj.324.7329.71.

3. Hirsh J., Guyatt G., Albers G.W., Harrington R., Schünemann H.J. Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):110S-112S. https://doi.org/10.1378/chest.08-0652.

4. Gaziano J.M., Brotons C., Coppolecchia R., Cricelli C., Darius H., Gorelick P.B. et al. Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE): A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet. 2018;392(10152):1036–1046. https://doi.org/10.1016/S0140-6736(18)31924-X.

5. McNeil J.J., Wolfe R., Woods R.L., Tonkin A.M., Donnan G.A., Nelson M.R. et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018;379(16):1509–1518. https://doi.org/10.1056/NEJMoa1805819.

6. Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Goldberger Z.D., Hahn E.J. et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177-e232. https://doi.org/10.1016/j.jacc.2019.03.010.

7. Bowman L., Mafham M., Wallendszus K., Stevens W., Buck G., Barton J. et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018;379(16):1529–1539. https://doi.org/10.1056/NEJMoa1804988.

8. Cosentino F., Grant P.J., Aboyans V., Bailey C.J., Ceriello A., Delgado V. et al. 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486.

9. Yusuf S., Joseph P., Dans A., Gao P., Teo K., Xavier D. et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. 2021;384(3):216–228. https://doi.org/10.1056/NEJMoa2028220.

10. Lewis H.D. Jr, Davis J.W., Archibald D.G., Steinke W.E., Smitherman T.C., Doherty J.E. 3rd et al. Protective Effects of Aspirin against Acute Myocardial Infarction and Death In men with Unstable Angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309(7):396–403. https://doi.org/10.1056/NEJM198308183090703.

11. Cairns J.A., Gent M., Singer J., Finnie K.J., Froggatt G.M., Holder D.A. et al. Aspirin, Sulfinpyrazone, or Both in Unstable Angina. Results of a Canadian Multicenter Trial. N Engl J Med. 1985;313(22):1369–1375. https://doi.org/10.1056/NEJM198511283132201.

12. Théroux P., Ouimet H., McCans J., Latour J.G., Joly P., Lévy G. et al. Aspirin, Heparin, or Both to Treat Acute Unstable Angina. N Engl J Med. 1988;319(17):1105– 1111. https://doi.org/10.1056/NEJM198810273191701.

13. The RISC Group. Risk of Myocardial Infarction and Death during Treatment with Low Dose Aspirin and Intravenous Heparin in Men with Unstable Coronary Artery Disease. Lancet. 1990;336(8719):827–830. Available at: https://pubmed.ncbi.nlm.nih.gov/1976875.

14. Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither among 17,187 Cases of Suspected Acute Myocardial Infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2(8607):349–360. Available at: https://pubmed.ncbi.nlm.nih.gov/2899772.

15. CAPRIE Steering Committee. A Randomised, Blinded, Trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet. 1996;348(9038):1329–1339. https://doi.org/10.1016/s0140-6736(96)09457-3.

16. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N Engl J Med. 2001;345(7):494–502. https://doi.org/10.1056/NEJMoa010746.

17. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K. et al. Effects of Pretreatment with Clopidogrel and Aspirin Followed by Long-Term Therapy in Patients Undergoing Percutaneous Coronary Intervention: the PCI-CURE Study. Lancet. 2001;358(9281):527–533. https://doi.org/10.1016/s0140-6736(01)05701-4.

18. Borja J., García O., Donado E., Izquierdo I. Clopidogrel and Metoprolol in Myocardial Infarction. Lancet. 2006;367(9513):811–812. https://doi.org/10.1016/S0140-6736(06)68327-X.

19. Mehta S.R., Tanguay J.F., Eikelboom J.W., Jolly S.S., Joyner C.D., Granger C.B. et al. Double-Dose versus Standard-Dose Clopidogrel and High-Dose versus LowDose Aspirin in Individuals Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes (CURRENT-OASIS 7): A Randomised Factorial Trial. Lancet. 2010;376(9748):1233–1243. https://doi.org/10.1016/S0140-6736(10)61088-4.

20. Wiviott S.D., Braunwald E., McCabe C. H., Montalescot G., Ruzyllo W., Gottlieb S. et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007;357(20):2001–2015. https://doi.org/10.1056/NEJMoa0706482.

21. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C. et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2009;361(11):1045–1057. https://doi.org/10.1056/NEJMoa0904327.

22. O’Donoghue M.L., Murphy S.A., Sabatine M.S. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients after Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Circulation. 2020;142(6):538–545. https://doi.org/10.1161/CIRCULATIONAHA.120.046251.

23. Collet J.P., Thiele H., Barbato E., Barthélémy O., Bauersachs J., Bhatt D.L. et al. 2020 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation. Eur Heart J. 2021;42(14):1289–1367. https://doi.org/10.1093/eurheartj/ehaa575.

24. Dewilde W.J., Oirbans T., Verheugt F.W., Kelder J.C., De Smet B.J., Herrman J.P. et al. Use of Clopidogrel with or without Aspirin in Patients Taking Oral Anticoagulant Therapy and Undergoing Percutaneous Coronary Intervention: An Open-Label, Randomised, Controlled Trial. Lancet. 2013;381(9872):1107–1115. https://doi.org/10.1016/S0140-6736(12)62177-1.

25. Gibson C.M., Mehran R., Bode C., Halperin J., Verheugt F.W., Wildgoose P. et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375(25):2423– 2434. https://doi.org/10.1056/NEJMoa1611594.

26. Cannon C.P., Bhatt D.L., Oldgren J., Lip G.Y. H., Ellis S.G., Kimura T. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017;377(16):1513–1524. https://doi.org/10.1056/NEJMoa1708454.

27. Lopes R.D., Heizer G., Aronson R., Vora A.N., Massaro T., Mehran R. et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380(16):1509–1524. https://doi.org/10.1056/NEJMoa1817083.

28. Vranckx P., Valgimigli M., Eckardt L., Tijssen J., Lewalter T., Gargiulo G. et al. Edoxaban-Based versus Vitamin K Antagonist-Based Antithrombotic Regimen after Successful Coronary Stenting in Patients with Atrial Fibrillation (ENTRUST-AF PCI): A Randomised, Open-Label, Phase 3b Trial. Lancet. 2019;394(10206):1335–1343. https://doi.org/10.1016/S0140-6736(19)31872-0.

29. Panchenko E.P. Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention: What Has Changed in the Guidelines in 2020? Aterotromboz = Atherothrombosis. 2020;(2):56– 64. (In Russ.) https://doi.org/10.21518/2307-1109-2020-2-56-64.

30. Lopes R.D., Leonardi S., Wojdyla D.M., Vora A.N., Thomas L., Storey R.F. et al. Stent Thrombosis in Patients with Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation. 2020;141(9):781–783. https://doi.org/10.1161/CIRCULATIONAHA.119.044584.

31. Alexander J.H., Wojdyla D., Vora A.N., Thomas L., Granger C.B., Goodman S.G. et al. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients with Atrial Fibrillation Early and Late after an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. Circulation. 2020;141(20):1618–1627. https://doi.org/10.1161/CIRCULATIONAHA.120.046534.

32. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.

33. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C. et al. 2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes. Eur Heart J. 2020;41(3):407–477. https://doi.org/10.1093/eurheartj/ehz425.

34. Panchenko E.P. Results of Three Year Observation of Outpatients with Clinical Manifestations of Atherothrombosis (Analysis of Russian Population of REACH Registry). Kardiologiya = Cardiology. 2009;(10):9–15. (In Russ.) Available at: https://elibrary.ru/item.asp?id=16545990.

35. Steg P.G., Bhatt D.L., Wilson P.W., D’Agostino R. Sr, Ohman E.M., Röther J. et al. One-Year Cardiovascular Event Rates in Outpatients with Atherothrombosis. JAMA. 2007;297(11):1197–1206. https://doi.org/10.1001/jama.297.11.1197.

36. Komarov A.L., Korobkova V.V., Shakhmatova O.O., Yarovaya E.B., Samko A.N., Panchenko E.P. Peripheral Arterial Diseases and the Risk of Thrombotic Outcomes in Patients after Scheduled Percutaneous Coronary Interventions (According to Results of Prospective Study). Kardiologicheskiy vestnik = Russian Cardiology Bulletin. 2020;16(1):72–80. (In Russ.) https://doi.org/10.36396/MS.2020.16.1.010.

37. Udell J.A., Bonaca M.P., Collet J.P., Lincoff A.M., Kereiakes D.J., Costa F. et al. Long-Term Dual Antiplatelet Therapy for Secondary Prevention of Cardiovascular Events in the Subgroup of Patients with Previous Myocardial Infarction: A Collaborative Meta-Analysis of Randomized Trials. Eur Heart J. 2016;37(4):390–399. https://doi.org/10.1093/eurheartj/ehv443.

38. Eikelboom J.W., Connolly S.J., Bosch J., Dagenais G.R., Hart R.G., Shestakovska O. et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319–1330. https://doi.org/10.1056/NEJMoa1709118.

39. Aboyans V., Ricco J.B., Bartelink M.E. L., Björck M., Brodmann M., Cohnert T. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration with the European Society for Vascular Surgery (ESVS): Document Covering Atherosclerotic Disease of Extracranial Carotid and Vertebral, Mesenteric, Renal, Upper and Lower Extremity Arteries. Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816. https://doi.org/10.1093/eurheartj/ehx095.

40. Anand S.S., Bosch J., Eikelboom J.W., Connolly S.J., Diaz R., Widimsky P. et al. Rivaroxaban with or without Aspirin in Patients with Stable Peripheral or Carotid Artery Disease: An International, Randomised, Double-Blind, Placebo-Controlled Trial. Lancet. 2018;391(10117):219–229. https://doi.org/10.1016/S0140-6736(17)32409-1.

41. Conte M.S., Bradbury A.W., Kolh P., White J.V., Dick F., Fitridge R. et al. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg. 2019;58(1S):S1.e33-S109. e33. https://doi.org/10.1016/j.ejvs.2019.05.006.